Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 1 | Investing.com | ||
20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha | ||
07.08. | Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat | 1 | Investing.com | ||
07.08. | Phathom Pharmaceuticals GAAP EPS of -$1.05 misses by $0.01, revenue of $39.5M beats by $3.92M | 2 | Seeking Alpha | ||
PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
07.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.08. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
28.07. | Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 | 2 | GlobeNewswire (USA) | ||
23.06. | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 263 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
19.06. | Phathom Q1 2025: VOQUEZNA-Akzeptanz steigt, Unternehmen strebt Profitabilität für 2026 an | 5 | Investing.com Deutsch | ||
16.06. | Phathom says FDA confirmed Voqueza exclusivity through May 2032 | 1 | Seeking Alpha | ||
16.06. | Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA | - | RTTNews | ||
16.06. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.06. | H.C. Wainwright maintains Buy on Phathom stock, $20 target | 3 | Investing.com | ||
09.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Phathom-Aktie mit Kursziel von 20 US-Dollar | 1 | Investing.com Deutsch | ||
09.06. | Goldman Sachs erhöht Kursziel für Phathom nach FDA-Exklusivitätsentscheidung | 4 | Investing.com Deutsch | ||
06.06. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
06.06. | Guggenheim bekräftigt Kaufempfehlung für Phathom-Aktie nach FDA-Exklusivitätszusage | 18 | Investing.com Deutsch | ||
06.06. | Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity | 6 | Investing.com | ||
06.06. | Stifel-Analysten bekräftigen Kaufempfehlung für Phathom Pharmaceuticals-Aktie | 4 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INOVIO PHARMACEUTICALS | 2,320 | +2,65 % | Inovio: Fortschritte bei DNA-Medizin und Zulassungsantrag für INO-3107 in Aussicht | ||
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 14,840 | +0,92 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
IBIO | 0,735 | -2,65 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
MYRIAD GENETICS | 5,850 | -0,85 % | Myriad Genetics, Inc.: Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology | SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
ADAPTIMMUNE THERAPEUTICS | 0,044 | +1,15 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
BIOXCEL THERAPEUTICS | 3,000 | -0,83 % | BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia | BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p Complete resolution of agitation was significantly higher... ► Artikel lesen | |
ROCKET PHARMACEUTICALS | 2,746 | +1,18 % | Rocket Pharmaceuticals announces CFO resignation | ||
MACROGENICS | 1,494 | 0,00 % | MacroGenics, Inc.: MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities | Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement... ► Artikel lesen | |
SPERO THERAPEUTICS | 1,676 | +1,33 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
SCILEX | 25,250 | +0,48 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders | ||
INVIVYD | 1,295 | 0,00 % | Invivyd auf H.C. Wainwright Konferenz: Strategische Expansion über COVID-19 hinaus | ||
GENERATION BIO | 6,090 | 0,00 % | Generation Bio Co.: Generation Bio Announces 1-for-10 Reverse Stock Split | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases... ► Artikel lesen |